Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda’s Dengue Vaccine Secures Positive Opinion in EU
October 18, 2022
- Mitsubishi Tanabe’s Neuromyelitis Optica Spectrum Disorder Med Approved in Taiwan
October 18, 2022
- Shionogi Eyes FY2024 Japan Filing of Regeneration-Inducing Medicine
October 17, 2022
- Fujifilm Ditches Avigan COVID-19 Program, Pulls Submission in Japan
October 17, 2022
- Shionogi’s COVID Pill Effective for Non-Omicron Variants Too: President
October 14, 2022
- Fertility Drugs Face Supply Woes as Demand Spikes on Health Coverage
October 14, 2022
- Pfizer Seeks Japan Nod for BA.4/5-Tailored Vaccine for Ages 5-11
October 13, 2022
- Shionogi Delays Filing Plan for COVID-19 Vaccine to “By End of 2022”
October 13, 2022
- Shionogi to Test COVID Pill as Prophylaxis for Household Contacts from December
October 13, 2022
- Takeda to Discontinue Zejula Capsules, Urges Switch to Tablet Version
October 12, 2022
- Viatris Group to End Sale of 33 Products for Various Reasons
October 12, 2022
- Teikoku Seiyaku Pulls Plug on Kampo Business
October 12, 2022
- Kyushu Univ. Spinoff Aims to File NK-Like Cells in 2025, Eyes Combo with Checkpoint Drugs
October 11, 2022
- Japan Ethical Drug Sales Rise 6.3% in August: Crecon
October 11, 2022
- Moderna Probing Correlations between Spikevax Adverse Reactions and Immune Response: SVP
October 7, 2022
- Opdivo Top-Selling Drug in Japan for 9 Consecutive Months: Encise
October 7, 2022
- Santen’s Glaucoma Drug Accepted for Review in Europe
October 7, 2022
- Fujifilm to Launch Domestic Bio-CDMO Site in FY2026 to Bolster Vaccine Production
October 7, 2022
- Sumitomo to Incur 54 Billion Yen in Impairment Loss on Kynmobi
October 7, 2022
- Towa’s Win in Livalo Damage Suit Now Final and Binding
October 7, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…